SCHEMBL10140405

SCHEMBL10140405

COc1c(-c2ccccc2)nn(C)c1-c1nc2ccc(C(C)=O)cc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 9/20 0.48
TP53 P04637 2/20 0.46
MAPT P10636 1/20 0.46
COMT P21964 1/20 0.46
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
RAB9A P51151 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7961586 0.93 CHEK2 (0.53) CHEK2HDAC3HDAC1HDAC8HDAC6
SCHEMBL7960793 0.91 KDM4E (0.52) CHEK2TP53MAPTCOMTHDAC3
SCHEMBL7966206 0.91 CHEK2 (0.61) CHEK2
SCHEMBL7959385 0.89 CHEK2 (0.57) CHEK2TP53MAPTCOMTHDAC3
SCHEMBL10139875 0.89 HDAC6 (0.49) CHEK2TP53MAPTHDAC3HDAC1
SCHEMBL10140880 0.88 CYP3A4 (0.43) CHEK2TP53MAPTCOMTHDAC6
SCHEMBL7982191 0.85 P2RY6 (0.51) TP53MAPTKDM4ENPC1ALDH1A1
SCHEMBL10139799 0.84 NPC1 (0.65) TP53MAPTKDM4ENPC1ALDH1A1
SCHEMBL10140879 0.82 POLB (0.48) CHEK2TP53MAPTHDAC3HDAC1
SCHEMBL10140458 0.81 MAPT (0.46) TP53MAPTCOMTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 CHEK2 4794/4885TP53 4367/4885MAPT 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.